Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas.
Johnny Duerinck
No relevant relationships to disclose
Stephanie Du Four
No relevant relationships to disclose
An Van Binst
No relevant relationships to disclose
Hendrik Everaert
No relevant relationships to disclose
Alex Michotte
No relevant relationships to disclose
Jean D'haens
No relevant relationships to disclose
Bart Neyns
Research Funding - Pfizer